Elderly
FDA
Discover Early Risks of Mild Cognitive Impairment (MCI) and Seize Early Treatment Opportunities to Delay Disease Progression
BDR Technology Overview (Free On-Site Trials Available May 16-18)
Electroencephalography (EEG) signals are one of the effective tools for diagnosing brain disorders. The BDR system is FDA approved in the United States and utilizes a 5-minute EEG collection followed by AI analysis to calculate the probabilities of normal and mild brain degeneration, continuously monitoring degenerative trends. This technology offers a non-invasive, convenient, safe screening process with clinical data validation, achieving an accuracy rate of 84%. BDR has successfully overcome the challenges of traditional methods in identifying early brain degeneration, representing an innovative application of medical technology in early screening.
[2] Wijaya A, Setiawan NA, Ahmad AH, Zakaria R, Othman Z. Electroencephalography and mild cognitive impairment research: A scoping review and bibliometric analysis (ScoRBA). AIMS Neurosci. 2023 Jun 13;10(2):154-171. doi: 10.3934/Neuroscience.2023012. PMID: 37426780; PMCID: PMC10323261.
Achieve Early and Accurate Assessment of Brain Degeneration Risk to Delay and Prevent Ongoing Deterioration!
SMART solution for use by medical institutions and elderly care service organizations.
For more information, please contact:
(852) 9711 9922